2024
Impact of Decarceration Plus Alcohol, Substance Use, and Mental Health Screening on Life Expectancies of Black Sexual Minority Men and Black Transgender Women Living With HIV in the United States: A Simulation Study Based on HPTN 061
Feelemyer J, Bershteyn A, Scheidell J, Brewer R, Dyer T, Cleland C, Hucks-Ortiz C, Justice A, Mayer K, Grawert A, Kaufman J, Braithwaite S, Khan M. Impact of Decarceration Plus Alcohol, Substance Use, and Mental Health Screening on Life Expectancies of Black Sexual Minority Men and Black Transgender Women Living With HIV in the United States: A Simulation Study Based on HPTN 061. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 95: 283-290. PMID: 38032748, PMCID: PMC10922416, DOI: 10.1097/qai.0000000000003354.Peer-Reviewed Original ResearchConceptsLower life expectancyBlack sexual minority menBlack transgender womenReduce incarcerationSubstance useTransgender WomenIncreased LEVeterans Aging Cohort StudyPsychiatric conditionsMental health screeningLinkage to treatmentDisproportionate rates of incarcerationLife expectancyAging Cohort StudyRates of incarcerationHistory of incarcerationSexual minority menImplementing screeningHealth screeningSubstance use disordersTreatment of psychiatric conditionsPositive screenImprove screeningCohort studyDisproportionate rates
2019
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Althoff KN, Chandran A, Zhang J, Arevalo WM, Gange SJ, Sterling TR, Gill MJ, Justice AC, Palella FJ, Rebeiro PF, Silverberg MJ, Mayor AM, Horberg MA, Thorne JE, Rabkin CS, Mathews WC, Klein MB, Humes E, Lee J, Hogg R, Moore RD, Research and Design of IeDEA N. Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal Of Epidemiology 2019, 188: 2097-2109. PMID: 31602475, PMCID: PMC7036649, DOI: 10.1093/aje/kwz232.Peer-Reviewed Original ResearchConceptsAlcohol-related deathsInjection drug useKey populationsLife expectancyDrug useHuman immunodeficiency virusLife expectancy benefitAge 20 yearsCause of deathCurrent opioid epidemicAlcohol-related mortalityAntiretroviral treatmentImmunodeficiency virusOpioid epidemicExpected life expectancyWhite womenSubstance useWhite menComparison groupDrugsDeathPLWHLife expectancy disparityMenBlack men
2017
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survivalHealth-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study
Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, Lima VD, Ahmed T, Kendall CE, Althoff KN, Justice AC, Barrios R, Shoveller J, Montaner JSG, study C. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. The Lancet HIV 2017, 4: e270-e276. PMID: 28262574, PMCID: PMC5761654, DOI: 10.1016/s2352-3018(17)30029-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultBritish ColumbiaFemaleHIV InfectionsHumansLife ExpectancyMaleMiddle AgedRetrospective StudiesYoung AdultConceptsHealth-adjusted life expectancyActive antiretroviral therapySelect comorbiditiesHIV statusLife expectancyGeneral populationPopulation-based observational cohort studyShorter overall life expectancyHIV-negative counterpartsCase-finding algorithmHIV-negative menHIV-negative populationObservational cohort studyComplex care needsService delivery interventionsAge 20 yearsYears of ageCauses of comorbidityShort life expectancyOverall life expectancyHealthy stateElectronic health recordsAntiretroviral therapyCohort studyRetrospective cohort
2015
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d’Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015, 29: 221-229. PMID: 25426809, PMCID: PMC4284008, DOI: 10.1097/qad.0000000000000540.Peer-Reviewed Original ResearchConceptsMortality rate ratiosCardiovascular diseaseLife expectancyBackground populationNon-AIDS malignanciesAntiretroviral therapy initiationProportion of smokersNorth American cohortSmoking-related mortalityCause of deathMore life yearsAIDS malignanciesAntiretroviral therapyPrevious smokersTherapy initiationSmoking cessationSmoking increasesExcess mortalityAge 35HIVSmokersAmerican cohortSmokingLife yearsHigh mortality
2013
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, Research and Design of IeDEA F. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLOS ONE 2013, 8: e81355. PMID: 24367482, PMCID: PMC3867319, DOI: 10.1371/journal.pone.0081355.Peer-Reviewed Original ResearchMeSH KeywordsAdultCanadaFemaleHIV InfectionsHumansLife ExpectancyMaleMiddle AgedUnited StatesYoung AdultConceptsAntiretroviral therapyHIV-positive adultsMortality rateLife expectancyNorth American AIDS Cohort CollaborationHIV transmission risk groupTransmission risk groupsCombination antiretroviral therapyInjection drug useHIV-positive individualsCrude mortality rateComparable life expectancyBaseline CD4Cohort CollaborationART initiationCD4 countAge-specific mortality ratesRisk groupsPositive adultsGeneral populationDrug useAge 20Cells/AdultsAdditional yearCohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug useManagement of Human Immunodeficiency Virus Infection in Advanced Age
Greene M, Justice AC, Lampiris HW, Valcour V. Management of Human Immunodeficiency Virus Infection in Advanced Age. JAMA 2013, 309: 1397-1405. PMID: 23549585, PMCID: PMC3684249, DOI: 10.1001/jama.2013.2963.Peer-Reviewed Original ResearchConceptsHIV-positive patientsOlder HIV-positive patientsHuman immunodeficiency virus (HIV) infectionHIV-negative counterpartsComorbid medical illnessesHIV-negative patientsComorbid medical conditionsImmunodeficiency virus infectionHuman immunodeficiency virusLife expectancyMultiple comorbid diseasesLonger life expectancyAntiretroviral regimenOlder HIVAntiretroviral therapyComorbid diseasesConcomitant diseasesPositive patientsMedical illnessImmunodeficiency virusAdvanced ageChronic diseasesChronic illnessConsensus statementVirus infectionLifetime Drinking Trajectories Among Veterans in Treatment for HIV
Jacob T, Blonigen DM, Upah R, Justice A. Lifetime Drinking Trajectories Among Veterans in Treatment for HIV. Alcohol Clinical And Experimental Research 2013, 37: 1179-1187. PMID: 23448171, PMCID: PMC5596456, DOI: 10.1111/acer.12071.Peer-Reviewed Original ResearchConceptsSevere chronicHIV diagnosisLate onsetVeterans Aging Cohort StudyYoung adultsCourse of drinkingAging Cohort StudyOnset of HIVOnset of treatmentPatterns of drinkingLifetime Drinking HistoryHIV groupCohort studyHIV- participantsTreatment outcomesHIVCurrent studyYounger ageCocaine useDrinking historyDrinking phasesLatent growth mixture modelMedical issuesLonger durationDrinking trajectories
2010
Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value?
Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value? Value In Health 2010, 13: 535-542. PMID: 20345544, PMCID: PMC3032536, DOI: 10.1111/j.1524-4733.2010.00714.x.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionNonadherent patientsAdherence interventionsRelative riskRisk factorsAntiretroviral therapy adherence interventionsEffect sizeNonadherence risk factorsBehavioral risk factorsHIV careAntiretroviral adherencePatientsNonadherenceSocietal perspectiveIncremental costIntervention costsSmall effect sizesLife expectancyInterventionRisk reductionPlausible effect sizes
2009
Do Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence?
Braithwaite RS, Roberts MS, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Nucifora K, Justice AC. Do Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence? Clinical Infectious Diseases 2009, 48: 822-826. PMID: 19210173, PMCID: PMC3032571, DOI: 10.1086/596768.Peer-Reviewed Original Research
2008
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Annals Of Internal Medicine 2008, 148: 178-85. PMID: 18252681, PMCID: PMC3124094, DOI: 10.7326/0003-4819-148-3-200802050-00004.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral loadHIV treatmentEarly treatmentEarly initiationLife expectancyVeterans Aging Cohort StudyChronic HIV infectionCombination antiretroviral therapyEarly treatment initiationAging Cohort StudyTherapy-related toxicityAge 40 yearsQuality-adjusted life expectancyAge 30 yearsBase-case analysisCohort studyHIV infectionTreatment initiationCopies/Current recommendationsLate treatmentImportant harmsTherapyTreatment
2007
A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care
Braithwaite RS, Concato J, Chang CC, Roberts MS, Justice AC. A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care. JAMA Internal Medicine 2007, 167: 2361-2365. PMID: 18039996, PMCID: PMC3460384, DOI: 10.1001/archinte.167.21.2361.Peer-Reviewed Original ResearchConceptsCongestive heart failureHuman immunodeficiency virusComorbidity-adjusted life expectancyColorectal cancer screeningColorectal cancerClinical guidelinesCancer screeningLife expectancyHeart failureComorbidity profilesImmunodeficiency virusPoint of careIndividual patientsPatientsIncremental benefitCancerComorbiditiesWomenMenGuidelinesExpectancyPayoff timeScreeningYearsCare